Health Highlights: Feb. 21, 2020
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Alzheimer's Gene Mapping Project Proposed in New York State A proposed project to map the genes of 1 million people in New York living with or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 21, 2020 Category: General Medicine Source Type: news

Alzheimer's Gene Mapping Project Proposed in New York State
Title: Alzheimer's Gene Mapping Project Proposed in New York StateCategory: Health NewsCreated: 2/21/2020 12:00:00 AMLast Editorial Review: 2/21/2020 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - February 21, 2020 Category: Geriatrics Source Type: news

Stalked by the Fear That Dementia Is Stalking You
Testing for Alzheimer ’s disease and other forms of dementia is hardly foolproof, and could even backfire. (Source: NYT Health)
Source: NYT Health - February 20, 2020 Category: Consumer Health News Authors: Judith Graham, Kaiser Health News Tags: Alzheimer ' s Disease Families and Family Life Memory Elderly Dementia Genetics and Heredity Anxiety and Stress Living Wills and Health Care Proxies Diet and Nutrition Depression (Mental) Frontotemporal Dementia Brain Nursing H Source Type: news

Can Hearing Aids Help Prevent Dementia?
Research suggests that paying more attention to the “invisible disability” of hearing loss might improve our brains. (Source: NYT Health)
Source: NYT Health - February 20, 2020 Category: Consumer Health News Authors: Kim Tingley Tags: Ears and Hearing Alzheimer ' s Disease Dementia Hearing Aids Brain Source Type: news

A deep dive into cellular aging
(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell's nucleus--and identified an FDA-approved drug that helped suppress the damaging effects of the condition in cells and mice. The discovery, published in Genes& Development, could lead to treatments that promote healthy aging or prevent age-associated diseases such as cancer, Alzheimer's disease, heart disease and more. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2020 Category: International Medicine & Public Health Source Type: news

MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
(University of Texas M. D. Anderson Cancer Center) MD Anderson announces a strategic research collaboration with Denali Therapeutics to develop new targeted therapies for Alzheimer's and other neurodegenerative diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

Hispanics/Latinos underrepresented in Alzheimer's disease research
(University of Houston) The largest ethnic minority in the US, at 18% of the population, Hispanics/Latinos are 50% more likely to develop Alzheimer's disease than non-Hispanic whites, yet they comprise less than 1% of clinical trials for Alzheimer's. A University of Houston researcher is set on changing that, by increasing health literacy among Hispanics/Latinos and closing the health disparity gap. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 20, 2020 Category: International Medicine & Public Health Source Type: news

Two grants will fund research into neurotechnology, drug delivery system
(Beckman Institute for Advanced Science and Technology) Hyunjoon (Joon) Kong's group will collaborate on two grants with other researchers at the Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-Champaign. The National Science Foundation will fund the investigation into how neurons and muscle cells communicate with each other. The Alzheimer's Foundation will support research to develop a drug delivery system that can be used to treat Alzheimer's disease. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 20, 2020 Category: International Medicine & Public Health Source Type: news

As Prices Rise for Parkinson's, Alzheimer's Meds, Patients Go Without
WEDNESDAY, Feb. 19, 2020 -- Rising drug costs are hampering the care of patients with debilitating neurological disorders like Parkinson's disease and Alzheimer's, a new study finds. Patients are less likely to fill necessary prescriptions as... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 19, 2020 Category: General Medicine Source Type: news

One drug, many diseases
(American Chemical Society) It seems too good to be true: a single drug that could treat humanity's worst afflictions, including atherosclerosis, cancer, Alzheimer's, Parkinson's and arthritis. All of these diseases have one thing in common -- they involve an inflammatory protein called NLRP3. Now, biotech start-ups and pharmaceutical companies are racing to develop drugs that inhibit the function of this protein, according to an article inChemical& Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.   (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Neighborhood features and one's genetic makeup interact to affect cognitive function
(Florida Atlantic University) Few studies have examined how the neighborhood's physical environment relates to cognition in older adults. Researchers categorized 4,716 individuals by apolipoprotein E (APOE) genotype -- a genetic risk factor for Alzheimer's disease (AD) to determine if there are cognitive benefits of living in neighborhoods with greater access to social, walking and retail destinations. Results showed that the positive influence of neighborhood environments on cognition are strongest among those who are at the lowest risk for AD, specifically APOEε2 carriers. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 19, 2020 Category: International Medicine & Public Health Source Type: news

Amyloid PET results prompt adults to rethink their future
When PET scans reveal elevated amyloid levels in cognitively normal older adults,...Read more on AuntMinnie.comRelated Reading: FDG-PET shows where exercise could stall Alzheimer's PET, MRI link amyloid plaque with swift decline Who should get brain scans for Alzheimer's disease? PET, MRI show physical activity aids brain health Would high amyloid level spur physician-assisted death? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 18, 2020 Category: Radiology Source Type: news

AHA News: Diabetes, Alzheimer's Together Might Increase Stroke Severity
Title: AHA News: Diabetes, Alzheimer's Together Might Increase Stroke SeverityCategory: Health NewsCreated: 2/17/2020 12:00:00 AMLast Editorial Review: 2/18/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 18, 2020 Category: Cardiology Source Type: news

Despite a marked reduction in the prevalence of dementia, the number of people with dementia is set to double by 2050 according to new Alzheimer Europe report
(Alzheimer Europe) Today, at a European Parliament lunch debate, Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates for dementia in Europe. The report findings show that, despite a marked reduction in the prevalence of dementia, the number of people with dementia is nonetheless set to double by 2050. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 18, 2020 Category: International Medicine & Public Health Source Type: news

AHA News: Diabetes, Alzheimer's Together Might Increase Stroke Severity
MONDAY, Feb. 17, 2020 (American Heart Association News) -- Bleeding strokes are the deadliest type of stroke and the hardest to treat. What might make matters worse is having both diabetes and Alzheimer's disease versus either condition alone, new... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 17, 2020 Category: General Medicine Source Type: news

Beta-arrestin-2 increases neurotoxic tau driving frontotemporal dementia
(University of South Florida (USF Health)) The proteinβ-arrestin-2 increases the accumulation of brain-damaging tau tangles, a cause several forms of dementia, by interfering with removal of excess tau from the brain, a new study by the University of South Florida Health (USF Health) Morsani College of Medicine found. The research suggests a new treatment approach that could be preventive for those at risk or with mild cognitive impairment, and also for those with Alzheimer's disease and other overt dementias caused by tau. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2020 Category: International Medicine & Public Health Source Type: news

Who is man's best friend? To some people with dementia, it's a robot dog
(Natural News) A California company is marketing a robotic dog they’re developing to be a best friend that can comfort people who are living with Alzheimer’s disease and other forms of dementia. The makers said that this robot dog will be able to provide companionship for people by responding to human voice and touch with “life-like motions.” Entrepreneur Tom... (Source: NaturalNews.com)
Source: NaturalNews.com - February 16, 2020 Category: Consumer Health News Source Type: news

Effect of dual-tasking on walking and cognitive demands in adults with Alzheimer's dementia experienced in using a 4-wheeled walker - Hunter SW, Omana H, Madou E, Wittich W, Hill KD, Johnson AM, Divine A, Holmes JD.
BACKGROUND: Learning to walk with a 4-wheeled walker increases cognitive demands in people with Alzheimer's dementia (AD). However, it is expected that experience will offset the increased cognitive demand. Current research has not yet evaluated gait in pe... (Source: SafetyLit)
Source: SafetyLit - February 15, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Pathological links between traumatic brain injury and dementia: Australian pre-clinical research - Collins JM, Woodhouse A, Bye N, Vickers J, King AE, Ziebell J.
Traumatic brain injury (TBI) can cause persistent cognitive changes and ongoing neurodegeneration in the brain. Accumulating epidemiological and pathological evidence implicates TBI in the development of Alzheimer's disease (AD), the most common cause of d... (Source: SafetyLit)
Source: SafetyLit - February 15, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Alzheimer ’s Research UK seeks to improve early detection of disease with new global project
The initiative will aim to attract up to £100m in investment by 2030 to support these efforts.  (Source: mobihealthnews)
Source: mobihealthnews - February 14, 2020 Category: Information Technology Source Type: news

Subtle decline in cognition predicts progression to Alzheimer's pathology
(University of California - San Diego) Researchers at UC San Diego School of Medicine report that abnormal levels of beta-amyloid plaques in brain predict cognitive decline and higher risk of developing Alzheimer's disease, but also that cognitive performance predicts progression from normal to abnormal levels of beta-amyloid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 14, 2020 Category: International Medicine & Public Health Source Type: news

Alzheimer's and dementia: Caregiver depression
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - February 14, 2020 Category: Consumer Health News Source Type: news

Upstate breaks ground on Nappi Longevity Institute
Project will provide critical care and medical advancements in brain health to combat Alzheimer's and related diseases. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 13, 2020 Category: Universities & Medical Training Tags: News Source Type: news

Wearable to spot Alzheimer's being developed
Five million healthy volunteers will be used to map signs of the disease years before symptoms develop. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 13, 2020 Category: Consumer Health News Source Type: news

Can bilingualism protect the brain even with early stages of dementia?
A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of dementia, making up 60 to 70 per cent of dementia cases. Of all activities with neuroplastic benefits, language use is the most sustained, consuming the largest proportion of time within a day. It also activates regions across the entire brain. (Source: World Pharma News)
Source: World Pharma News - February 13, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Genetic Testing for Alzheimer Disease: Challenges and Ethics Genetic Testing for Alzheimer Disease: Challenges and Ethics
Advances in genomics have increased interest in predictive genetic testing for Alzheimers, but concerns remain regarding the accuracy of such tests, their regulation, and potential ethical issues.Current Opinion in Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2020 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Ceramides predict vascular brain injury and dementia
(Brigham and Women's Hospital) In a study published in Annals of Clinical and Translational Neurology, a team led by investigators from Brigham and Women's Hospital describes the role of plasma ceramides in dementia and Alzheimer's disease (AD) and their potential as a blood-based biomarker. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2020 Category: International Medicine & Public Health Source Type: news

Timing of brain cell death uncovers a new target for Alzheimer's treatment
(Tokyo Medical and Dental University) Alzheimer's disease affects millions of people worldwide and is characterized by neuron loss and beta-amyloid plaque formation in the brain. Researchers led by Tokyo Medical and Dental University have now found that neuron degeneration beings much earlier than originally thought and is dependent on a protein called YAP. Supplementation with a YAP analog restored cognitive function and prevented neuron loss in Alzheimer's disease mice, paving the way for novel human therapeutics. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 13, 2020 Category: International Medicine & Public Health Source Type: news

PET shows cardiac meds may reduce beta-amyloid buildup
Patients who were on cardiovascular medications like cholesterol-lowering drugs...Read more on AuntMinnie.comRelated Reading: Amyloid-PET advocates take their case to Congress PET/MRI sheds light on cerebral vascular risk factors PET model tracks beta amyloid, Alzheimer's risk Florbetapir-PET links lack of financial acumen to dementia Alzheimer's biomarkers could affect races differently (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 12, 2020 Category: Radiology Source Type: news

Seminal, Highly Anticipated Alzheimer's Trial Falters Seminal, Highly Anticipated Alzheimer's Trial Falters
Top-line results from the phase 2/3 DIAN-TU trial show that neither of two investigational drugs met primary or key secondary outcomes in patients with dominantly inherited Alzheimer's disease.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - February 11, 2020 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news

An Alzheimer ’s Treatment Fails: ‘We Don’t Have Anything Now’
With high hopes, drugs to fight brain plaques were tested in people genetically destined to develop dementia. The drugs failed. (Source: NYT Health)
Source: NYT Health - February 11, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Alzheimer ' s Disease Elderly Drugs (Pharmaceuticals) Brain Clinical Trials Dominantly Inherited Alzheimer Network (DIAN) Eli Lilly and Company National Institute on Aging Roche Holding AG Washington University Source Type: news

Alzheimer ’s treatment led by Wash U researcher fails
A study of whether drugs could slow or stop cognitive decline in patients with a genetic mutation guaranteeing they'd develop dementia has failed. Dr. Randall Bateman, a neurologist at Washington University, told the New York Times he was “shocked” when he first saw the data: “It was really crushing,” he said. Still, the Times reports that the scientists believe the drugs may have been given at too low a dose or could be given to yo unger patients. Participating in the trial at Washington… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 11, 2020 Category: Pharmaceuticals Authors: Jacob Kirn Source Type: news

Triad health system to study mice brains in Alzheimer's research
A five-year, $2.53 million grant from the National Institute on Aging will give Wake Forest Baptist Health researchers a leg up in defining early indicators of Alzheimer ’s disease.  The study will look at the way microscopic tubes in the brain deteriorate over time, a potential early indicator of Alzheimer’s. “Microtubules are message carriers within neurons that are very tightly bundled in a healthy brain,” said Kiran Solingapuram Sai, Ph.D. Sai, the p roject’s lead investigator, is… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 11, 2020 Category: Pharmaceuticals Authors: John Joyce Source Type: news

Two Experimental Drugs Disappoint With Inherited Alzheimer's
Title: Two Experimental Drugs Disappoint With Inherited Alzheimer'sCategory: Health NewsCreated: 2/10/2020 12:00:00 AMLast Editorial Review: 2/11/2020 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - February 11, 2020 Category: Geriatrics Source Type: news

Scientists develop non-invasive method to predict onset of dementia
(Regenstrief Institute) Information gathered from routine visits to the doctor is enough to accurately predict a person's risk of developing Alzheimer's disease and related dementias, according to new research led by scientists from Regenstrief Institute, Indiana University and Merck. The researchers developed and tested machine learning algorithms using data from electronic medical records to identify patients who may be at risk for developing the dementia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Blood-based multiplexed diagnostic sensor helps to accurately detect Alzheimer's disease
(The Korea Advanced Institute of Science and Technology (KAIST)) A research team at KAIST reported clinically accurate multiplexed electrical biosensor for detecting Alzheimer's disease by measuring its core biomarkers using densely aligned carbon nanotubes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 11, 2020 Category: Biology Source Type: news

An Alzheimer ’s Drug Trial Fails: ‘We Don’t Have Anything Now’
With high hopes, drugs to fight brain plaques were tested in people genetically destined to develop dementia. The drugs failed. (Source: NYT Health)
Source: NYT Health - February 11, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Alzheimer ' s Disease Elderly Drugs (Pharmaceuticals) Brain Clinical Trials Dominantly Inherited Alzheimer Network (DIAN) Eli Lilly and Company National Institute on Aging Roche Holding AG Washington University Source Type: news

Disappointing results from two experimental Alzheimer drugs
Two drugs failed to prevent or slow mental decline in a study of people with a genetic predisposition to develop Alzheimer's disease at a relatively young age. (Source: L.A. Times - Health)
Source: L.A. Times - Health - February 10, 2020 Category: Consumer Health News Authors: Associated Press Source Type: news

Disappointing results from two experimental Alzheimer drugs
Two drugs failed to prevent or slow mental decline in a study of people with a genetic predisposition to develop Alzheimer's disease at a relatively young age. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - February 10, 2020 Category: Science Authors: Associated Press Source Type: news

Two Experimental Drugs for Rare, Inherited Alzheimer Disease Disappoint
MONDAY, Feb. 10, 2020 -- Two experimental drugs do not appear to slow memory loss or mental decline in patients in the early stages of a rare, inherited, early-onset form of Alzheimer disease, according to initial results from a clinical trial. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 10, 2020 Category: Pharmaceuticals Source Type: news

Which herbal treatments in TCM help boost memory?
(Natural News) Mild cognitive impairment (MCI) is defined as the transitional stage between cognitive decline caused by aging and severe cognitive decline caused by brain disorders, such as Alzheimer’s disease and dementia. Research suggests that the prevalence of MCI increases with age, affecting about 25.2 percent of adults between the ages of 80 and 84.... (Source: NaturalNews.com)
Source: NaturalNews.com - February 10, 2020 Category: Consumer Health News Source Type: news

Two Experimental Drugs Disappoint With Inherited Alzheimer's
MONDAY, Feb. 10, 2020 -- Two experimental drugs do not appear to slow memory loss or mental decline in patients in the early stages of a rare, inherited form of Alzheimer's disease, according to initial results from a clinical trial. The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 10, 2020 Category: General Medicine Source Type: news

Drugs fail to slow decline in inherited Alzheimer's disease
Two experimental drugs have failed to prevent or slow mental decline in a study of people who are virtually destined to develop Alzheimer's disease at a relatively young age because of rare gene flaws (Source: ABC News: Health)
Source: ABC News: Health - February 10, 2020 Category: Consumer Health News Tags: Health Source Type: news

Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
Study with novel trial design did not meet primary endpoint INDIANAPOLIS, Feb. 10, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medici... Biopharmaceuticals, Neurology Eli Lilly, solanezumab, Alzheimer's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 10, 2020 Category: Pharmaceuticals Source Type: news

Roche drug fails in early-onset Alzheimer's disease study
Roche's experimental drug gantenerumab failed to slow cognitive decline in people with a rare inherited form of Alzheimer's disease, the latest setback for companies hunting for a cure for the devastating brain-wasting disease. (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer ’s disease
Basel, 10 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer ’s disease (AD). This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease.1 The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Co...
Source: Roche Media News - February 10, 2020 Category: Pharmaceuticals Source Type: news

Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer ’s disease
Basel, 10 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer ’s disease (AD). This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease.1 The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Co...
Source: Roche Investor Update - February 10, 2020 Category: Pharmaceuticals Source Type: news

A happy partner leads to a healthier future
(Michigan State University) Michigan State University research found that those who are optimistic contribute to the health of their partners, staving off the risk factors leading to Alzheimer's disease, dementia and cognitive decline as they grow old together. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 10, 2020 Category: International Medicine & Public Health Source Type: news

Dementia charity leads global initiative for wearables to revolutionize disease detection
(Alzheimer's Research UK) The UK's leading dementia research charity Alzheimer's Research UK has today launched a global initiative to revolutionize the early detection of neurodegenerative diseases like Alzheimer's. The project will harness and analyse a wealth of digital data to develop signatures of disease -- or 'fingerprints' -- that can be then detected using wearable technologies, such as smart watches. Initial funds towards the initiative have already been secured from Bill Gates and Iceland Foods Charitable Foundation. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 10, 2020 Category: International Medicine & Public Health Source Type: news

Dementia symptoms: Losing these items around the house may be a sign of Alzheimer’s diseas
DEMENTIA is a progressive disease that can be hard to spot when symptoms first begin. This is because forgetfulness - the first symptom of Alzheimer's - can be part and parcel with everyday life. (Source: Daily Express - Health)
Source: Daily Express - Health - February 9, 2020 Category: Consumer Health News Source Type: news